Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

James Harris

Nurse Practitioner Derry, NH Nurse Practitioner

NPI 1932186475 CMS profile 11042537

15 Tsienneto Rd Ste 200, Derry, NH 03038

Open in the dashboard

General payments

$325

11 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Harris of Derry, NH is reported in the CMS Open Payments database as having received $325 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34 2
2023 General $224 5
2022 General $67 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Harris
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to James Harris were reported at $34. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year James Harris Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $67 $152 $48–$470 $149
2023 $224 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $34 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Sanofi-Aventis U.S. LLC $121 1 payment
  2. Medtronic, Inc. $85 5 payments
  3. CeQur Corporation $44 1 payment
  4. Xeris Pharmaceuticals, Inc. $41 2 payments
  5. Beta Bionics, Inc. $20 1 payment
  6. Novo Nordisk Inc $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $325 11 payments
Products named General payments · program years 2022–2025
  1. TZIELD $121 1 payment
  2. CeQur Simplicity $44 1 payment
  3. GVOKE HYPOPEN $41 2 payments
  4. INPEN SMART INSULIN DELIVERY SYSTEM $39 2 payments
  5. MINIMED 770G $28 2 payments
  6. iLet Bionic Pancreas Automated insulin delivery system $20 1 payment
  7. iLet Bionic Pancreas Automated insulin delivery system $20 1 payment
  8. iLet Bionic Pancreas Automated insulin delivery system $20 1 payment
  9. iLet Insulin Infusion Kit Inset $20 1 payment
  10. iLet Insulin Infusion Kit Contact Detach $20 1 payment
  11. Other $46 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

862

Median for Nurse Practitioner: 389

Drug cost

$730,821

Median for Nurse Practitioner: $21,885

Branded share of claims

81%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 96 $148,368
Jardiance Empagliflozin Brand 95 $118,148
Mounjaro Tirzepatide Brand 89 $107,712
Trulicity Dulaglutide Brand 38 $61,596
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 36 $45,571
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 26 $44,305
Tresiba Flextouch U-200 Insulin Degludec Brand 28 $36,920
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 14 $34,837
Humalog Kwikpen U-200 Insulin Lispro Brand 25 $34,670
Lyumjev Kwikpen U-200 Insulin Lispro-Aabc Brand 17 $18,067

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$102,832

Medicare's payments for the services billed

Medicare patients

226

Average age 71

Services billed

1,598

109 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 46%
Chronic kidney disease 39%
Ischemic heart disease 31%
Depression 31%
Heart failure 27%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record